Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956325 | 0.83 | KMT2A (0.49) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29952474 | 0.83 | KMT2A (0.49) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1273278 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2ASMN1; SMN2SOAT1 | |
| SCHEMBL253718 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2ASMN1; SMN2SOAT1 | |
| SCHEMBL11996779 | 0.81 | GPR88 (0.62) | GPR88METAP2METAP1 | |
| SCHEMBL14521519 | 0.81 | ALDH1A1 (0.58) | GPR88ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL13035553 | 0.81 | GPR88 (0.62) | GPR88METAP2METAP1 | |
| SCHEMBL13302598 | 0.81 | ALDH1A1 (0.58) | GPR88ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11996754 | 0.81 | GPR88 (0.62) | GPR88METAP2METAP1 | |
| SCHEMBL2786917 | 0.79 | KDM4E (0.55) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124613-B2 | Spirotropane compounds | VIROCHEM PHARMA INC. (CA) | 2012-02-28 | — | — | US | disclosed |
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2007143847-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | CCR5, CXCR1, CXCR2 | GPR88 155/4885ALDH1A1 622/4885LMNA 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.